

▶ ▶ ▶ ▶

▶ ▶ ▶

▶ ▶ ▶ ▶

▶

▶ ▶


# Declaration of War on Cancer

---

“

moon should be turned toward conquering this dread disease. Let us make a total national commitment to achieve this goal.”

# Incidence & Mortality of Cancer 1975 – 2007





“

cancer death rates continue to drop, but to accelerate the decline.”

## Lifetime Probability of Developing Cancer, Men, 2004-2006\*

Site	Risk
All sites <sup>†</sup>	1 in 2
Prostate	1 in 6
Lung and bronchus	1 in 13
Colon and rectum	1 in 19
Urinary bladder <sup>‡</sup>	1 in 26
Melanoma <sup>§</sup>	1 in 37
Non-Hodgkin lymphoma	1 in 44
Kidney	1 in 55
Leukemia	1 in 66
Oral Cavity	1 in 72
Stomach	1 in 90

\* For those free of cancer at beginning of age interval.

† All Sites exclude basal and squamous cell skin cancers and in situ cancers except urinary bladder.

‡ Includes invasive and in situ cancer cases

§ Statistic for white men.

Source: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.4.0 Statistical Research and Applications Branch, NCI, 2009. <http://srab.cancer.gov/devcan>

## Lifetime Probability of Developing Cancer, Women, US, 2004-2006\*

Site	Risk
All sites <sup>†</sup>	1 in 3
Breast	1 in 8
Lung & bronchus	1 in 16
Colon & rectum	1 in 20
Uterine corpus	1 in 40
Non-Hodgkin lymphoma	1 in 52
Urinary bladder <sup>‡</sup>	1 in 84
Melanoma <sup>§</sup>	1 in 56
Ovary	1 in 71
Pancreas	1 in 72
Uterine cervix	1 in 145

\* For those free of cancer at beginning of age interval.

† All Sites exclude basal and squamous cell skin cancers and in situ cancers except urinary bladder.

‡ Includes invasive and in situ cancer cases

§ Statistic for white women.

Source: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.4.0 Statistical Research and Applications Branch, NCI, 2009. <http://srab.cancer.gov/devcan>

# My Personal Story



oni . ay . angskau  
merican cancer ociety cancer ction . etwork (. . . )  
ead for . innesota's . . . . .

# My Story As An Advocate

- ...
- ...
- ...
- ...


# ACS CAN's Federal Priorities

---




# Twelve Steps To FDA Approval

- 1. Target identification
- 2. Target validation
- 3. Hit identification
- 4. Hit validation
- 5. Lead identification
- 6. Lead optimization
- 7. Preclinical testing
- 8. IND application
- 9. Phase 1 clinical trials
- 10. Phase 2 clinical trials
- 11. Phase 3 clinical trials
- 12. NDA application
- 13. FDA review
- 14. FDA approval



## Trends in Cancer Survival by Age Group, Children 0-14 Years, 1975-2005



\*5-year relative survival rates, based on follow up of patients through 2005.

Source: Surveillance, Epidemiology, and End Results Program, 1975-2006, Division of Cancer Control and Population Sciences, National Cancer Institute, 2009.

# 2011 State Legislative Priorities

- 
- - 
  - 
  - 
  -

- 
- - 
  - 
  - 
  -

# Legislative Successes In The States

---

- -
- -
- -

# For More Information

...

...

...

---

...

...

...

---

...

